Telemedically Assisted Sampling of COVID-19 Patients - Is the Sampling Quality Sufficient

COVID-19 Clinical Trial

Official title:

Telemedically Assisted Sampling of COVID-19 Patients - Is the Sampling Quality Sufficient: An Interventional Randomized Method Comparison Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05386407
• Other study ID #: 2021-02508
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 14, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2023
• Source: Teststation Praxis Dr. med Bielecki
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) pandemic has resulted in more than 3.8 billion registered tests, 275 million positive cases, and 5 million deaths worldwide. Early and regular testing has been an important pillar of secondary prevention since the beginning.

However, this pandemic has also fostered solutions in the form of e telemedicine with enormously increased applicability.

The question of whether telemedically supervised testing with SARS-CoV-2 Rapid Antigen Tests is non-inferior to the same tests being carried out by trained personnel in test centers is still unanswered.

With this study, the investigators aim to compare and evaluate the reliability and sampling quality of telemedically guided self-performed rapid tests for professional use compared to professional sampling by healthcare personnel.

Our hypothesis is that, applying a strict standard operating procedure (SOP, attached), guided oropharyngeal + nasal (OP+N) self-sampling (GSS) is non-inferior to nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP), and that guided OP+N sampling is superior to unsupervised OP+N self-sampling (USS).

Description:

BACKGROUND AND PROJECT RATIONALE

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) pandemic has resulted in more than 3.8 billion registered tests, 275 million positive cases, and 5 million deaths worldwide. Early and regular testing has been an important pillar of secondary prevention since the beginning.

However, this pandemic has also fostered solutions in the form of e telemedicine with enormously increased applicability.

Several emerging issues, such as the use of technology by older adults, the availability of high-capacity Internet access, and support for telemedicine, can be overcome in the near future to increase the benefits of telemedicine.

The question of whether telemedically supervised testing with SARS-CoV-2 Rapid Antigen Tests is non-inferior to the same tests being carried out by trained personnel in test centers is still unanswered.

With this study, the investigators aim to compare and evaluate the reliability and sampling quality of telemedically guided self-performed rapid tests for professional use compared to professional sampling by healthcare personnel.

Our hypothesis is that, applying a strict standard operating procedure (SOP, attached), guided oropharyngeal + nasal (OP+N) self-sampling (GSS) is non-inferior to nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP), and that guided OP+N sampling is superior to unsupervised OP+N self-sampling (USS).

PROJECT OBJECTIVES AND DESIGN 2.1 Hypothesis and primary objective

Our hypothesis is that, applying a strict standard operating procedure (SOP, attached), guided oropharyngeal + nasal (OP+N) self-sampling (GSS) is non-inferior to nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP), and that guided OP+N sampling is superior to unsupervised OP+N self-sampling (USS).

OP+N GSS is non-inferior to nasopharyngeal (NP) sampling performed by HCP

OP+N GSS is non-inferior to OP+N performed by HCP

OP+N GSS is superior to unsupervised OP+N USS

The investigators are also interested to know if the difference between the sampling techniques is the same depending on the SARS-CoV-2 viral load (low, medium, high).

Another secondary endpoint will be in how many people a correctly executed nasopharyngeal sampling is possible. Due to lack of comfort, deviation of septum, as well as nasal polyps in a small percent of the population, the investigators hypothesize that in a majority of people it is not possible to correctly execute a nasopharyngeal sampling.

2.2 Primary and secondary endpoints

The Ct-value is defined as the number of cycles required for a signal to cross the detection threshold and can be used as a surrogate for sampling quality, as it allows to quantify the amount of material that is being extracted.

Primary endpoints:

Concordance of positive/negative samples in antigen tests with GSS, USS, and HCP-based samples.

Secondary endpoints:

Housekeeping gene Ct comparison based on sampling method between samples based on GSS, USS, or HCP ORF1ab/RdRp-, E-, N-, and S genes Ct value comparison based on sampling method between samples based on GSS, USS, or HCP Qualitative analysis of perceived sampling accuracy established with a short form Detected variant of concern Case report form (CRF) assessing basic demographics and variables of interests as indicated separately in the CRF form Prevalence of variants of concern Immunization status Travel destinations in the passed three months n of people in which a nasopharyngeal sampling is possible correctly (ratio) 2.3 Project design

This is a single-center, randomized, controlled study at a Swiss test station.

2.3.1 Piloting

In order to assess the sampling quality by HCP or telemedically guided self-sampling, Ct values obtained in RT-PCR analysis of a COVID-19 assay, a housekeeping gene can be used for reference.

Hence, for the first part of the study, the investigators will recruit 10 people in which the investigators will perform an OP+N sampling at two-time points, 15 minutes apart, and compare the Ct values of these two values to calculate the standard deviation and see if the produced SD*1.96/√(Sample size) equals the margin of error. Our 95% confidence interval (CI) will be standard deviation (SD)+/- the margin of error.

Alternatively, the investigators will pool confirmed RT-PCRs of two/three swab samples into one and spike them with SARS-CoV-2 standard. Next, the investigators do as many repeats of the same sample on RT-PCR comparing housekeeper and SARS-CoV-2 genes. The advantage here is that the investigators will have controlled starting biological material and the resultant SD / 95% CI will concern only the analytical and laboratory process variability. With the first approach, the investigators will test SD of the swab procurer too, along with the interference coming from the analytical process (lab, instruments, sample storage).

2.3.2. Randomized telemedical and HCP sampling

After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.

After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP.

The investigators will start the assessment with the self-sampling methods in order to reduce bias that could occur if they experience the HCP's sampling.

Written instructions on how to perform a self-test will be provided, representing the instructions that come along with a commercially available rapid test set. An instructional online video tutorial or similar would also account as the latest state of the art.30 However, this has not yet been implemented comprehensively with all available test sets that are currently being distributed across Switzerland.

Furthermore, to avoid bias in the sampling procedure, exclusively one HCP at the testing station will be designated as the study's sampling expert. The HCP will perform the NP and OP+N sampling sequentially in a previously randomized order.

The telemedical guidance will be exclusively done by the same HCP in order to minimize interoperability differences. The standardized telemedical sampling will be conducted at the same test station, in a separate empty room in which a computer will be placed with instructions on how to connect for the telemedical consultation.

During each sampling procedure, the patients will either undergo OP+N GSS or OP+N USS for PCR analysis, as well as for antigenic testing. This means each participant will be sampled a total of six times within 15 minutes from different locations in the upper respiratory tract. Concordance of results between sampling by GSS vs. USS vs. HCPs will be assessed.

As the difference in time between the samplings can influence the Ct value, the sampling process will only be started when the HCP and the telemedical supervisor are ready. The three different samples will be stored in the test station refrigerator between 2°C-8°C before transport.

A grouping of samples will ensure that temperature changes are consistent between samples from the same participant.

PROJECT POPULATION AND STUDY PROCEDURES 3.1 Project population, inclusion and exclusion criteria

All patients, regardless of symptoms, who present themselves at the Test-station SARS-CoV-2 testing will be offered to participate in the study.

Study inclusion criteria; Written informed consent Patients visiting the test-station for a SARS-CoV-2 test Consent to comply with the study protocol Age of 18 or older

List the study exclusion criteria:

Refusal to comply with the study protocol Digital illiteracy (i.e. patients who would never use telemedicine as they do not feel competent enough to use the necessary tools) Not German or English speaking People trained in the use of rapid diagnostic tests (HCP, biologists) will be excluded to reduce bias30

3.2 Recruitment, screening and informed consent procedure All costs for tests performed within the framework of the study will be financed by the study. A payable travel certificate will be issued for unchanged costs. Participation in the study and spending time on it is voluntary, free of charge and at no cost to the study participants. However, each study participant will receive a voucher for free PCR testing at a later date.

Participants will not receive financial compensation for the participation in this study. However, each study participant will receive a voucher for free PCR testing at a later date.

The investigators shall end recruiting either when reaching the necessary sample size or no later than October 30th, 2022.

STATISTICS AND METHODOLOGY 4.1. Statistical analysis plan

4.1.1 Randomization

To ensure allocation concealment, randomization will be performed with a block of 170 in a 1:1 allocation ratio by a web-based independent randomization software (Random Allocation version 1.0). Patients will be randomly assigned to either OP+N GSS or to OP+N USS. Instruction on the assigned procedure will be kept in sealed opaque envelopes labeled with sequential study numbers and opened right before swab-testing.

4.1.2 Sample size

The SD of the mean of Ct values for RT-PCR analysis of multiple samples is not clearly defined in the literature and varies between studies.34,35

If there is truly no difference between the standard and experimental treatment, then 85 patients per group are required to be 90% sure that the lower limit of a one-sided 97.5% confidence interval (or equivalently a 95% two-sided confidence interval) will be above the non-inferiority limit of -3.

We, therefore, estimated a standard error of six that accounts for this variance. In addition, the limit of non-inferiority was set at three according to clinical significance.

Results will be stratified by symptom status, age, and sex.

4.1.3 Hypothesis

Primary outcome

NP HCP vs OP+N HCP H0: μe - μs ≤ -d -> μ(NP HCP ct) - μ(OP+N HCP ct) ≤ -3 H1: μe - μs > -d -> μ(NP HCP ct) - μ(OP+N HCP ct) > -3

OP+N HCP vs OP+N GSS

H0: μe - μs ≤ -d -> μ(OP+N HCP ct) - μ(OP+N GSS ct) ≤ -3 H1: μe - μs > -d -> μ(OP+N HCP ct) - μ(OP+N GSS ct) > -3

OP+N HCP vs OP+N USS

H0: μe - μs ≤ -d -> μ(OP+N HCP ct) - μ(OP+N USS ct) ≤ -3 H1: μe - μs > -d -> μ(OP+N HCP ct) - μ(OP+N USS ct) > -3

Secondary outcome:

We will stratify the primary outcome by viral load (low, medium, high).

4.1.4. Statistical test

A variant of a paired student t test or Wilcoxon test (if non-normal distribution) with exchange of null and alternative (relaxed) hypotheses will be used as a non-inferiority test to assess differences in cycle threshold (Ct, considered as a log2-transformed measure of the amount of viral RNA load) between the NP and OP/N samples (HCP and GSS). Stratification for possible confounders will be done using logistic regression.

In order to show agreement between the approaches and estimate the limits of agreement and those are not too large, different graphical methods, such as Bland Altman diagrams will be used to show agreement between the approaches.

4.2. Handling of missing data Analysis is based on intention-to-treat assumption. Collected data until drop-out will be included for further analysis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 170
• Est. completion date: December 31, 2025
• Est. primary completion date: October 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent

• Patients visiting the test-station for a SARS-CoV-2 test

• Consent to comply with the study protocol

• Age of 18 or older

Exclusion Criteria:

• Refusal to comply with the study protocol

• Digital illiteracy (i.e. patients who would never use telemedicine as they do not feel competent enough to use the necessary tools)

• Not German or English speaking

• People trained in the use of rapid diagnostic tests (HCP, biologists) will be excluded to reduce bias

Related Conditions & MeSH terms

• COVID-19
• Pharynx
• Telemedicine

Intervention

Diagnostic Test:
• telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)
After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS. After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP.

Locations

Country	Name	City	State
Switzerland	Teststation Praxis Dr. med Bielecki	Olten	Solothurn

Sponsors (1)

Lead Sponsor	Collaborator
Teststation Praxis Dr. med Bielecki

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NP HCP vs OP+N HCP	Concordance of positive/negative samples in antigen tests with nasopharyngeal sampling vs. oropharyngeal + nasal sampling, both performed by health care professionals	5 months
Primary	OP+N HCP vs OP+N GSS	Concordance of positive/negative samples in antigen tests with oropharyngeal + nasal sampling performed by health care professionals vs. oropharyngeal + nasal sampling telemedically guided self-sampling	5 months
Primary	OP+N HCP vs OP+N USS	Concordance of positive/negative samples in antigen tests with oropharyngeal + nasal sampling performed by health care professionals vs. unsupervised oropharyngeal + nasal self-sampling (USS)	5 months
Secondary	Housekeeping gene Ct comparison of oropharyngeal + nasal samples between guided self-sampling, unsupervised self-sampling, or sampling performed by health care professionals	Housekeeping gene Ct* comparison of oropharyngeal + nasal samples between guided self-sampling, unsupervised self-sampling, or sampling performed by health care professionals; *The Ct (cycle threshold) is defined as the number of cycles required for the viral genetic material to be detected above a certain level.	5 months
Secondary	ORF1ab/RdRp-, E-, N-, and S genes Ct value comparison based on sampling method between samples based on GSS, USS, or HCP	ORF1ab/RdRp-, E-, N-, and S genes Ct value comparison based on sampling method between samples based on GSS, USS, or HCP; Abbreviations: ORF1ab/RdRp-, E-, N-, and S genes are different houskeeping genes that serve as a reference level to compare the amount of the viral genetic material The Ct (cycle threshold) is defined as the number of cycles required for the viral genetic material to be detected above a certain level.; GSS: guided self-sampling USS: unsupervised self-sampling HCP: sampling performed by health care professionals	5 months
Secondary	Qualitative analysis of perceived sampling accuracy	Qualitative analysis of perceived sampling accuracy established with a short form	5 months
Secondary	Detected SARS-CoV-2 variants of concern	The detected SARS-CoV-2 Variants of Interest and Concern (VOC) is recorded. The WHO homepage is consulted for the specification: https://www.who.int/activities/tracking-SARS-CoV-2-variants	5 months
Secondary	CRF assessing basic demographics and variables of interests	Case report form (CRF) assessing basic demographics and variables of interests as indicated separately in the CRF form	5 months
Secondary	Prevalence of variants of concern	Prevalence of each detected variant of concern	5 months
Secondary	Immunization status regarding previous COVID-Vaccinations or previous COVID-19 disease(s)	Type and date of previous previous COVID-vaccinations and COVID-19 diseases basing on positive test results or detected serologic antibodies will be recorded. These facts are requested and verified with the respective patient-specific COVID certificate.	5 months
Secondary	Travel destinations in the passed three months	Travel destinations in the passed three months before the current sampling in the form of countries travelled to and, where appropriate, regions	5 months
Secondary	n of people in which a nasopharyngeal sampling is possible correctly (ratio)	n of people in which a nasopharyngeal sampling is possible correctly (ratio); - reason for impossible correct sampling would be anatomical variations of the nose or pathological anatomical conditions	5 months